Consensus Report of the 2015 Weinman International Conference on Mesothelioma
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
On November 9 and 10, 2015, the International Conference on Mesothelioma in Populations Exposed to Naturally Occurring Asbestiform Fibers was held at the University of Hawaii Cancer Center in Honolulu, Hawaii. The meeting was cosponsored by the International Association for the Study of Lung Cancer, and the agenda was designed with significant input from staff at the U.S. National Cancer Institute and National Institute of Environmental Health Sciences. A multidisciplinary group of participants presented updates reflecting a range of disciplinary perspectives, including mineralogy, geology, epidemiology, toxicology, biochemistry, molecular biology, genetics, public health, and clinical oncology. The group identified knowledge gaps that are barriers to preventing and treating malignant mesothelioma (MM) and the required next steps to address barriers. This manuscript reports the group's efforts and focus on strategies to limit risk to the population and reduce the incidence of MM. Four main topics were explored: genetic risk, environmental exposure, biomarkers, and clinical interventions. Genetics plays a critical role in MM when the disease occurs in carriers of germline BRCA1 associated protein 1 mutations. Moreover, it appears likely that, in addition to BRCA1 associated protein 1, other yet unknown genetic variants may also influence the individual risk for development of MM, especially after exposure to asbestos and related mineral fibers. MM is an almost entirely preventable malignancy as it is most often caused by exposure to commercial asbestos or mineral fibers with asbestos-like health effects, such as erionite. In the past in North America and in Europe, the most prominent source of exposure was related to occupation. Present regulations have reduced occupational exposure in these countries; however, some people continue to be exposed to previously installed asbestos in older construction and other settings. Moreover, an increasing number of people are being exposed in rural areas that contain noncommercial asbestos, erionite, and other mineral fibers in soil or rock (termed naturally occurring asbestos [NOA]) and are being developed. Public health authorities, scientists, residents, and other affected groups must work together in the areas where exposure to asbestos, including NOA, has been documented in the environment to mitigate or reduce this exposure. Although a blood biomarker validated to be effective for use in screening and identifying MM at an early stage in asbestos/NOA-exposed populations is not currently available, novel biomarkers presented at the meeting, such as high mobility group box 1 and fibulin-3, are promising. There was general agreement that current treatment for MM, which is based on surgery and standard chemotherapy, has a modest effect on the overall survival (OS), which remains dismal. Additionally, although much needed novel therapeutic approaches for MM are being developed and explored in clinical trials, there is a critical need to invest in prevention research, in which there is a great opportunity to reduce the incidence and mortality from MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076
Self-citationZalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968
Yang, H., Bocchetta, M., Kroczynska, B., Elmishad, A. G., Chen, Y., Liu, Z., Bubici, C., Mossman, B. T., Pass, H. I., Testa, J. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604008103 · Cited by 322
Self-citationThe deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1
Machida, Y. J., Machida, Y., Vashisht, A. A., Wohlschlegel, J. A., & Dutta, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.046755 · Cited by 274
Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma
Carbone, M., & Yang, H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2259 · Cited by 229
Self-citationRole of Mutagenicity in Asbestos Fiber-Induced Carcinogenicity and Other Diseases
Huang, S. X. L., Jaurand, M.-C., Kamp, D. W., Whysner, J., & Hei, T. K. (2011) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2011.556051 · Cited by 163
Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma
Xu, J., Kadariya, Y., Cheung, M., Pei, J., Talarchek, J., Sementino, E., Tan, Y., Menges, C. W., Cai, K. Q., Litwin, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1328 · Cited by 144 · cited 1×
“…(an amount that rarely caused MM in wild-type control mice) and on the basis of a study by the team of J. R. Testa, as described by Xu et al. 136 showing that BAP1 þ /- mice exposed to 3 m g of asbestos have a higher incidence of MM than control mice, it is anticipated that carriers of…”
Baumann, F., Buck, B. J., Metcalf, R. V., McLaurin, B. T., Merkler, D. J., & Carbone, M. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000506 · Cited by 128
Self-citationChoe, N., Tanaka, S., & Kagan, E. (1998) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.19.2.3111 · Cited by 95
DEPOSITION AND CLEARANCE OF CHRYSOTILE ASBESTOS*
(1994) · The Annals of Occupational Hygiene · doi:10.1093/annhyg/38.4.625 · Cited by 86
Cited by
BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
Bononi, A., Giorgi, C., Patergnani, S., Larson, D., Verbruggen, K., Tanji, M., Pellegrini, L., Signorato, V., Olivetto, F., Pastorino, S., et al. (2017) · Nature · doi:10.1038/nature22798 · Cited by 401
Self-citationMesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone, M., Adusumilli, P. S., Alexander, H. R., Baas, P., Bardelli, F., Bononi, A., Bueno, R., Felley‐Bosco, E., Galateau‐Salle, F., Jablons, D., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21572 · Cited by 335
Self-citationCarbone, M., Pass, H. I., Ak, G., Alexander, H. R., Baas, P., Baumann, F., Blakely, A. M., Bueno, R., Bzura, A., Cardillo, G., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.03.014 · Cited by 97
Tedesco, J., Jaradeh, M., & Vigneswaran, W. T. (2022) · Cancers · doi:10.3390/cancers14184415 · Cited by 12
Metadata
- Authors
- Carbone, M., Kanodia, S., Chao, A., Miller, A., Wali, A., Weissman, D., Adjei, A., Baumann, F., Boffetta, P., Buck, B., de Perrot, M., Dogan, A. U., Gavett, S., Gualtieri, A., Hassan, R., Hesdorffer, M., Hirsch, F. R., Larson, D., Mao, W., Masten, S., Pass, H. I., Peto, J., Pira, E., Steele, I., Tsao, A., Woodard, G. A., Yang, H., & Malik, S.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 11
- Issue
- 8
- Pages
- 1246-1262
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2500721338
- Cited by
- 144
- References
- 10
- FWCI
- 22.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Consensus Report of the 2015 Weinman International Conference on Mesothelioma. https://app.cochat.ai/papers/10.1016/j.jtho.2016.04.028
- The paper
- Carbone, M., Kanodia, S., Chao, A., Miller, A., Wali, A., Weissman, D., Adjei, A., Baumann, F., Boffetta, P., Buck, B., de Perrot, M., Dogan, A. U., Gavett, S., Gualtieri, A., Hassan, R., Hesdorffer, M., Hirsch, F. R., Larson, D., Mao, W., . . . Malik, S. (2016). Consensus Report of the 2015 Weinman International Conference on Mesothelioma. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2016.04.028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.